Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Equity Average (2021 - 2025)

Maravai Lifesciences Holdings (MRVI) has 5 years of Equity Average data on record, last reported at $228.9 million in Q4 2025.

  • For Q4 2025, Equity Average fell 51.19% year-over-year to $228.9 million; the TTM value through Dec 2025 reached $228.9 million, down 51.19%, while the annual FY2025 figure was $268.8 million, 51.79% down from the prior year.
  • Equity Average reached $228.9 million in Q4 2025 per MRVI's latest filing, down from $356.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $902.9 million in Q1 2023 and bottomed at $184.3 million in Q1 2021.
  • Average Equity Average over 5 years is $606.2 million, with a median of $646.2 million recorded in 2022.
  • Peak YoY movement for Equity Average: soared 225.49% in 2022, then plummeted 51.19% in 2025.
  • A 5-year view of Equity Average shows it stood at $501.3 million in 2021, then surged by 74.24% to $873.5 million in 2022, then dropped by 3.71% to $841.1 million in 2023, then plummeted by 44.24% to $469.0 million in 2024, then tumbled by 51.19% to $228.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $228.9 million in Q4 2025, $356.7 million in Q3 2025, and $499.1 million in Q2 2025.